Relmada Therapeutics Liabilities 2024

Relmada Therapeutics Aktienanalyse

What does Relmada Therapeutics do?

Relmada Therapeutics Inc is a biopharmaceutical company specializing in the development of medications for a variety of chronic pain and mental health disorders. The company is headquartered in New York, USA, and was founded in 2004. The history of Relmada Therapeutics Inc began with a focus on the development of NMDA receptor antagonists for the treatment of neuropathic pain. The company's main drug, d-Methadone, has been successfully tested in a Phase IIa clinical study and is now being tested in Phase IIb studies. Relmada Therapeutics Inc's business model is based on the development and commercialization of novel drugs targeting high medical needs. The company has a strong pipeline of pharmaceutical products in various clinical phases that can be used in pain management and mental health promotion. Relmada Therapeutics Inc generates revenue through the sale of patents and the out-licensing of their products to other pharmaceutical companies. In addition, the company pursues partnerships and joint ventures with other companies to further develop and market their products. Relmada Therapeutics Inc operates in three main divisions: pain therapy, mental health, and oncology. In pain therapy, the company has its main products, such as Oral Methadone and LevoCap ER, which help patients alleviate chronic pain. LevoCap ER is a long-acting, non-addictive pain medication that increases effectiveness and safety compared to other opioids. In the mental health field, Relmada Therapeutics Inc has developed QN-19, an overactive NMDA receptor blocker that represents a potential treatment option for depressive disorders. The company has also developed its new technology platform, mGluR2/3 agonists, which can be used in the treatment of anxiety and depression. In the oncology division, the company focuses on the development of innovative cancer treatments. The company is currently developing a new cancer drug that aims to overcome chemotherapy resistance. Relmada Therapeutics Inc is committed to providing innovative solutions to improve and enhance the quality of life for patients. The company relies on a strong research and development platform to develop medications targeting a variety of needs. The company is committed to continuing its research and development to provide innovative solutions that improve the treatment of chronic diseases. Answer: Relmada Therapeutics Inc is a biopharmaceutical company specializing in the development of medications for chronic pain and mental health disorders. The company is headquartered in New York, USA, and has a strong pipeline of pharmaceutical products in various clinical phases. They generate revenue through the sale of patents and partnerships with other companies, and their divisions focus on pain therapy, mental health, and oncology. They aim to provide innovative solutions to improve patient quality of life and continue research and development for better treatment options. Relmada Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Relmada Therapeutics's Liabilities

Relmada Therapeutics's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Relmada Therapeutics's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Relmada Therapeutics's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Relmada Therapeutics's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Relmada Therapeutics’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Relmada Therapeutics Stock

What is the level of liabilities of Relmada Therapeutics this year?

Relmada Therapeutics has a debt balance of 12.19 M USD this year.

What were the liabilities of Relmada Therapeutics compared to the previous year?

The liabilities of Relmada Therapeutics have increased by -2.44% dropped compared to the previous year.

What are the consequences of high debt for investors of Relmada Therapeutics?

High liabilities can pose a risk for investors of Relmada Therapeutics, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Relmada Therapeutics?

Low liabilities mean that Relmada Therapeutics has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Relmada Therapeutics affect the company?

An increase in liabilities of Relmada Therapeutics can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Relmada Therapeutics affect the company?

A decrease in the liabilities of Relmada Therapeutics can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Relmada Therapeutics?

Some factors that can influence the liabilities of Relmada Therapeutics include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Relmada Therapeutics so important for investors?

The liabilities of Relmada Therapeutics are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Relmada Therapeutics take to modify the liabilities?

To change its liabilities, Relmada Therapeutics can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Relmada Therapeutics pay?

Over the past 12 months, Relmada Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Relmada Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Relmada Therapeutics?

The current dividend yield of Relmada Therapeutics is .

When does Relmada Therapeutics pay dividends?

Relmada Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Relmada Therapeutics?

Relmada Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Relmada Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Relmada Therapeutics located?

Relmada Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Relmada Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Relmada Therapeutics from 5/4/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 5/4/2024.

When did Relmada Therapeutics pay the last dividend?

The last dividend was paid out on 5/4/2024.

What was the dividend of Relmada Therapeutics in the year 2023?

In the year 2023, Relmada Therapeutics distributed 0 USD as dividends.

In which currency does Relmada Therapeutics pay out the dividend?

The dividends of Relmada Therapeutics are distributed in USD.